You are here

  • Home
  • Archive
  • Volume 79, Issue Suppl 1
  • OP0223 EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND INADEQUATE RESPONSE TO BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (SELECT-PSA-2): A DOUBLE-BLIND, RANDOMIZED CONTROLLED PHASE 3 TRIAL

Article metrics

Article menu

Download PDFPDF

Scientific Abstracts
Oral Presentations
Update on new treatment options for psoriatic arthritis
OP0223 EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND INADEQUATE RESPONSE TO BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (SELECT-PSA-2): A DOUBLE-BLIND, RANDOMIZED CONTROLLED PHASE 3 TRIAL
Free

 

Online download statistics by month:

Online download statistics by month: June 2020 to May 2023

AbstractFullPdf
Jun 2020155032
Jul 2020154031
Aug 2020207046
Sep 2020343059
Oct 2020507074
Nov 2020531066
Dec 2020411063
Jan 2021355038
Feb 2021250033
Mar 2021325036
Apr 2021242043
May 202164021
Jun 20212033
Jul 202114019
Aug 202111020
Sep 202110023
Oct 2021137048
Nov 2021128027
Dec 2021156018
Jan 202272013
Feb 202290011
Mar 2022121040
Apr 20223707
May 2022107023
Jun 202298018
Jul 2022113015
Aug 20225008
Sep 202269011
Oct 20225705
Nov 202275015
Dec 20223405
Jan 20233406
Feb 20234505
Mar 20235003
Apr 20233102
May 20234508
Total51300925